APA (7th ed.) Citation

Adán-Castro, E., Zamora, M., Granados-Carrasco, D., Siqueiros-Márquez, L., García-Rodrigo, J. F., Macias, F., . . . Clapp, C. (2025). Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edema. Scientific Reports, 15(1), 1. https://doi.org/10.1038/s41598-025-12331-w

Chicago Style (17th ed.) Citation

Adán-Castro, Elva, et al. "Topical Ophthalmic Administration of the Antiangiogenic Peptide VIAN-c4551 Protects Against Experimental Diabetic Macular Edema." Scientific Reports 15, no. 1 (2025): 1. https://doi.org/10.1038/s41598-025-12331-w.

MLA (9th ed.) Citation

Adán-Castro, Elva, et al. "Topical Ophthalmic Administration of the Antiangiogenic Peptide VIAN-c4551 Protects Against Experimental Diabetic Macular Edema." Scientific Reports, vol. 15, no. 1, 2025, p. 1, https://doi.org/10.1038/s41598-025-12331-w.